bay2927088
HER2 Mutation
BayerPhase 2Active
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 51/ 100
- Competitive Position
- 95/ 100
Competitive context
10 Active assets in the HER2 Mutation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FULVESTRANT MedSIR | Phase 2 | CCC |
Zongertinib MedSIR | Phase 2 | CCC |
[14c]-bay2927088 Bayer | Phase 1 | CC |
bay2927088 coated Bayer | Phase 1 | CC |
Esomeprazole Bayer | Phase 1 | CC |
View all 10 →
Same molecule, other indications
bay2927088 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →